Opening plenary session features latest fetal fraction amplification researchSALT LAKE CITY, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc....
NASHVILLE, Tenn., Jan. 28, 2025 /PRNewswire/ -- The Women's Health research Collaborative (WHrC), a Petauri Kinect network of excellence, and...
Provides expecting parents with a concierge-level service model that delivers expert guidance, navigation and support for parental leave planningNEW YORK,...
Investigational Review Board (IRB) approval has been granted for the open-label study to evaluate tafenoquine for treatment of patients with...
Event will showcase results of Company's pivotal PRIME study and include the principal investigator SALT LAKE CITY, Jan. 27, 2025...
Conference call and webcast scheduled to take place on Wednesday, February 5, 2025, at 4:30 p.m. E.T.SCOTTSDALE, Ariz., Jan. 23,...
SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and...
REYKJAVIK, Iceland, Jan. 22, 2025 /PRNewswire/ -- Complete recombination map of the human-genome, a major step in genetics Scientists at...
PROVIDENCE, R.I., Jan. 22, 2025 /PRNewswire/ -- ParentData, the data-driven guide through pregnancy, parenthood, and beyond, has announced the relaunch of...
AUSTIN, Texas, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Tiny Health, a leader in at-home gut microbiome testing, today announced the...
PALO ALTO, Calif., Jan. 21, 2025 /PRNewswire/ -- Glooko, Inc., a global integrated digital health company connecting patients, providers, biopharma, and...
FemaSeed® patent application provides additional coverage for Femasys’ therapeutic option for women seeking infertility solution ATLANTA, Jan. 16, 2025 (GLOBE...
Series Recaps Biopharma, MedTech, and Science Trends and Breakthroughs That Shaped the Year LONDON, Jan. 16, 2025 /PRNewswire/ -- BioWorld™...
CAMPBELL, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of...
Reports $709 million in preliminary1 full-year 2024 U.S. net product revenues $611 million in SYFOVRE® U.S. net product revenues, including...
LAKELAND, Fla., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Lipozem emerges in an era where weight management solutions seem endless—from strict...
-- Preliminary unaudited net revenues from global sales of IMCIVREE® (setmelanotide) of approximately $42 million for the fourth quarter of...
Partnership could allow up to 35 million1 women in the menopause transition to connect with comprehensive access to specialized healthcare through innovative at-home testing...
Case reports published in medical literature suggest that tafenoquine combined with standard-of-care treatment exhibits a high cure rate in immunosuppressed...
GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the exercise of contract option...